- Record: found
- Abstract: not found
- Article: not found
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso ,
Gilbert H. Daniels ,
Kirstine Brown-Frandsen ,
Peter Kristensen ,
Johannes F.E. Mann ,
Michael A. Nauck ,
Steven E. Nissen ,
Stuart Pocock ,
Neil R. Poulter ,
Lasse S. Ravn ,
William M. Steinberg ,
Mette Stockner ,
Bernard Zinman ,
Richard M. Bergenstal ,
John B. Buse
July 28 2016
July 28 2016
Read this article at
ScienceOpenPublisher
- open (via free article)
- oa repository (via OAI-PMH doi match)
- oa repository (via OAI-PMH doi match)
- oa repository (via OAI-PMH doi match)
- oa repository (via OAI-PMH doi match)
- oa repository (via OAI-PMH doi match)
- oa repository (via OAI-PMH doi match)
- oa repository (via OAI-PMH doi match)
- oa repository (via OAI-PMH doi match)
- oa repository (via OAI-PMH doi match)
- oa repository (via pmcid lookup)
- oa repository (via OAI-PMH title and first author match)
Powered by 
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when
added to standard care in patients with type 2 diabetes, remains unknown.